Latest Conference Articles

June 29th 2017, 10:24pm

European Post-Chicago Melanoma / Skin Cancer Meeting

Jean Jacques Grob, MD, PhD, discusses the efficacy and tolerability of different doses of ipilimumab given in the adjuvant setting for patients with melanoma.

June 29th 2017, 10:00pm

ESMO Gastrointestinal Cancers Congress

The addition of pegvorhyaluronidase alfa (PEGPH20) to standard nab-paclitaxel/gemcitabine improved progression-free survival over standard therapy in patients with metastatic pancreatic ductal adenocarcinoma.

June 29th 2017, 9:55pm

ESMO Gastrointestinal Cancers Congress

Andrew E. Hendifar, MD, medical oncology lead for the Gastrointestinal Disease Research Group, Cedars-Sinai Medical Center, discusses HALO-202 in metastatic pancreatic ductal adenocarcinoma.

June 29th 2017, 9:51pm

ESMO Gastrointestinal Cancers Congress

Jordi Bruix, MD, head of the Barcelona Clinic Liver Cancer (BCLC) at University of Barcelona, discusses the updated findings of the RESORCE Trial in hepatocellular carcinoma.

June 29th 2017, 9:32pm

ESMO Gastrointestinal Cancers Congress

Combination therapy with AM0010, a PEGylated human interleukein (IL)-10, plus fluorouracil (5-FU), leucovorin, and oxaliplatin (FOLFOX) demonstrated encouraging clinical activity in metastatic pancreatic ductal adenocarcinoma.

June 29th 2017, 8:28pm

European Post-Chicago Melanoma / Skin Cancer Meeting

Alexander J. Stratigos, MD, University of Athens Medical School, discusses prevention techniques for melanoma.

June 29th 2017, 3:14pm

European Post-Chicago Melanoma / Skin Cancer Meeting

Paolo A. Ascierto, MD, National Tumour Institutue “Fondazione G. Pascale,” Unit of Melanoma, Naples, Italy, discusses the sequencing of targeted therapies for patients with melanoma.

June 27th 2017, 12:30am

European Hematology Association Congress

The first known trial of combined ublituximab (TG-1101), ibrutinib (Imbruvica), and umbralisib (TGR-1202) showed that the combination was well tolerated and had activity across heavily pretreated patients with high-risk B-cell malignancies.

June 26th 2017, 8:42pm

European Hematology Association Congress

Combination ibrutinib (Imbruvica) and venetoclax (Venclexta) set the bar high and aims to achieve eradication of minimal residual disease within a year of treatment in patients with relapsed or refractory chronic lymphocytic leukemia.

June 25th 2017, 11:54pm

European Hematology Association Congress

The combination of obinutuzumab and CC-122 was well tolerated and demonstrated promising response rates and durable remissions in patients with relapsed or refractory diffuse large B-cell lymphoma, follicular lymphoma, and marginal zone lymphoma.

June 25th 2017, 10:19pm

European Hematology Association Congress

Matthew J. Matasar, MD, discusses the potential of polatuzumab vedotin in patients with relapsed/refractory follicular lymphoma or diffuse large B-cell lymphoma.

June 25th 2017, 8:20pm

European Hematology Association Congress

Farhad Ravandi-Kashani, MD, professor, Department of Leukemia, The University of Texas MD Anderson Cancer Center, discusses vadastuximab talirine plus hypomethylating agents in acute myeloid leukemia.

June 25th 2017, 8:17pm

European Hematology Association Congress

Eric Smith, MD, PhD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses CD19 (19-28Z) CAR T-cell therapy in B-cell acute lymphoblastic leukemia.

June 25th 2017, 8:16pm

European Hematology Association Congress

CTL019, an investigational chimeric antigen receptor T-cell therapy, demonstrated high response rates and a manageable safety profile in pediatric and young adult patients with relapsed and/or refractory acute lymphoblastic leukemia.

June 25th 2017, 8:09pm

European Hematology Association Congress

Eunice Wang, MD, chief, Leukemia Service, professor of Oncology, Departments of Medicine and Immunology, Roswell Park Cancer Institute, discusses FLT3 mutations in acute myeloid leukemia.

June 24th 2017, 11:21pm

European Hematology Association Congress

Miguel-Angel Perales, MD, deputy chief, Adult Bone Marrow Transplant Service, director, Adult Bone Marrow Transplantation Fellowship Program, Memorial Sloan Kettering Cancer Center, discusses the remaining questions with CAR T-cell therapy in hematologic malignancies.

June 24th 2017, 11:19pm

European Hematology Association Congress

Christian Winther Eskelund, MD, Copenhagen University Hospital, Rigshospitalet, discusses a study of TP53 mutations in mantle cell lymphoma.

June 24th 2017, 10:46pm

European Hematology Association Congress

Paul A. Hamlin, MD, discusses his research with cerdulatinib in patients with certain types of non-Hodgkin lymphoma.

June 24th 2017, 10:30pm

European Hematology Association Congress

Results from the phase III Myeloma XI study showed that patients with myeloma had deeper responses after induction and after allo-stem cell transplantation with outpatient-delivered quadruplet therapy than with sequential immunomodulatory triplet combinations.

June 24th 2017, 9:11pm

European Hematology Association Congress

Patients with newly-diagnosed multiple myeloma who did not elect to undergo stem cell transplant but remained on single agent ixazomib maintenance fared as well as those who received SCT.